<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237887</url>
  </required_header>
  <id_info>
    <org_study_id>M03-656</org_study_id>
    <nct_id>NCT00237887</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
  <official_title>A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects&#xD;
      with Moderate to Severe Chronic Plaque Psoriasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving clinical response at Week 16 relative to the Baseline (Week 0) PASI score</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
  </secondary_outcome>
  <enrollment type="Actual">1212</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject was age 18 or older and in good health (Investigator discretion) with a recent&#xD;
             stable medical history.&#xD;
&#xD;
          -  Subject had a clinical diagnosis of psoriasis for at least 6 months, had moderate to&#xD;
             severe plaque psoriasis.&#xD;
&#xD;
          -  Subject was able and willing to self-administer sc injections or had available&#xD;
             qualified person(s) to administer sc injections&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject had previously received anti-TNF therapy.&#xD;
&#xD;
          -  Subject cannot discontinue systemic therapies and/or topical therapies for the&#xD;
             treatment of psoriasis and cannot avoid UVB or PUVA phototherapy&#xD;
&#xD;
          -  Subject cannot avoid excessive sun exposure&#xD;
&#xD;
          -  Subject is taking or requires oral or injectable corticosteroids&#xD;
&#xD;
          -  Subject considered by the investigator, for any reason, to be an unsuitable candidate&#xD;
             for the study&#xD;
&#xD;
          -  Female subject who is pregnant or breast-feeding or considering becoming pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Paperiello</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>October 7, 2005</study_first_submitted>
  <study_first_submitted_qc>October 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>August 28, 2007</last_update_submitted>
  <last_update_submitted_qc>August 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2007</last_update_posted>
  <keyword>Psoriasis</keyword>
  <keyword>adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

